Sugi Predict

Sugi Predict / Compounds / SCHEMBL17848653

SCHEMBL17848653

SCHEMBL17848653

CC(C)(C)OC(=O)N1CCC2(CC1)Cc1ccccc1O2

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 10/20 0.54
▸ IDO1 P14902 1/20 0.48
▸ HRH3 Q9Y5N1 1/20 0.48
▸ TRPM8 Q7Z2W7 2/20 0.46
▸ EPHX1 P07099 2/20 0.46
▸ EPHX2 P34913 2/20 0.46
▸ MAPK1 P28482 1/20 0.45
▸ SCN5A Q14524 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31094899 1.00 GPR119 (0.54) GPR119IDO1HRH3TRPM8EPHX1
SCHEMBL2745099 0.89 HRH3 (0.60) GPR119IDO1HRH3
SCHEMBL3702583 0.85 ATM (0.56) GPR119HRH3EPHX1EPHX2SCN5A
SCHEMBL19852497 0.85 HRH3 (0.53) GPR119HRH3EPHX1EPHX2MAPK1
SCHEMBL467280 0.85 ATM (0.56) GPR119HRH3EPHX1EPHX2SCN5A
SCHEMBL23110805 0.83 GPR119 (0.48) GPR119HRH3
SCHEMBL19030363 0.83 GPR119 (0.48) GPR119HRH3TRPM8EPHX2
SCHEMBL20270723 0.83 GPR119 (0.53) GPR119IDO1HRH3
SCHEMBL22520476 0.83 GPR119 (0.52) GPR119HRH3
SCHEMBL13919430 0.83 GPR119 (0.53) GPR119IDO1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-12448392-B2 Spiropiperidine derivatives CEPHALON LLC (US) 2025-10-21 — — US disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
WO-2025098503-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR 甘李药业股份有限公司 2025-05-15 — — WO disclosed
CN-112778276-B Compounds as SHP2 inhibitors and uses thereof 南京圣和药业股份有限公司 2024-08-20 — — CN disclosed
US-20240166661-A1 Spiropiperidine Derivatives CEPHALON LLC 2024-05-23 — — US disclosed
US-11878982-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2024-01-23 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-11498896-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2022-11-15 — — US disclosed
US-11046707-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2021-06-29 — — US disclosed
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2021-05-20 — — US disclosed
US-10633336-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-04-28 — — US disclosed
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON LLC 2020-01-30 — — US disclosed
EP-3554637-A1 SPIROPIPERIDINE DERIVATIVES 89Bio Ltd. (IL) 2019-10-23 — — EP disclosed
WO-2018112204-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON, INC. (US) 2018-06-21 — — WO disclosed
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2018-06-07 — — US disclosed
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2018-06-07 — — US disclosed
EP-3233077-A1 DOPAMINE D2 RECEPTOR LIGANDS The Broad Institute Inc. (US) 2017-10-25 — — EP disclosed
WO-2016100940-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, DRD3, ARRB1 GPR119 73/4885IDO1 993/4885HRH3 560/4885
US-11498896-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 GPR119 134/4885IDO1 1260/4885HRH3 305/4885
US-10633336-B2 Dopamine D2 receptor ligands DRD2, ARRB1, DRD3 GPR119 145/4885IDO1 1702/4885HRH3 730/4885
US-11878982-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 GPR119 354/4885IDO1 3262/4885HRH3 4629/4885
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 GPR119 134/4885IDO1 1260/4885HRH3 305/4885
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 GPR119 134/4885IDO1 1260/4885HRH3 305/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 GPR119 134/4885IDO1 1260/4885HRH3 305/4885
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES FASN, FADS2, SCD5 GPR119 354/4885IDO1 3262/4885HRH3 4629/4885
US-12448392-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 GPR119 354/4885IDO1 3262/4885HRH3 4629/4885
US-20240166661-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 GPR119 354/4885IDO1 3262/4885HRH3 4629/4885
US-11046707-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 GPR119 354/4885IDO1 3262/4885HRH3 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.